T-cell Depleted Alternative Donor Transplantation

Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase II Study Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00968864
• Other study ID #: LCH BMT 09-01
• Status: Terminated
• Phase: Phase 2
• Start date: August 2009
• Est. completion date: November 2016

Study information

• Verified date: October 2017
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose is to determine the ability of CD34+ selection and T cell depletion using the CliniMACS® device to prevent severe acute graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from an alternative (unrelated and mismatched related) donor. The secondary objectives include evaluation of engraftment, immune recovery, and post-transplant infections. Patients requiring stem cell transplants for either malignant (cancerous) or non-malignant disease will be included in the study. The recipients will be grouped into one of two groups based on whether the donor is mismatched related (Cohort A) or unrelated (Cohort B). The patient will receive a conditioning regimen including chemotherapy drugs and/or total body irradiation based on the disease for which the transplant is performed.

Description:

A major issue in alternative donor (mismatched related and unrelated donor transplantation is the development of graft-versus-host disease (GVHD). Several clinical trials have shown that the use of T-cell depleted peripheral blood stem cells (PBSC) reduces GVHD in alternative donor transplants. The purpose of this study is to determine the ability of CD34 positive selection and T cell depletion using the CliniMACS® Device as the only GVHD prophylaxis to prevent severe acute GVHD in recipients of an alternative donor PBSC transplant. Mismatched related donors will match at least 3 of 6 Human leukocyte antigens(HLA)(haplocompatible) and unrelated donors will match at least 6 out of 8 HLA antigens with the transplant recipient. The conditioning therapy including chemotherapy, anti-thymocyte globulin (ATG), +/- total body irradiation (TBI) will be based on the patient's diagnosis. The transplant recipient will be followed for 5 years after transplant for GVHD, engraftment, post-transplant infections, disease relapse, and overall survival. In addition, this study will serve as a platform for a companion study of therapy to accelerate immune recovery after transplant.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 53
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 30 Years

Eligibility

Inclusion Criteria:

• Age < 30 years
• Patient must have a malignant or non-malignant disease that can benefit from alternative stem cell transplantation. Examples include acute and chronic leukemias, myelodysplastic syndrome, lymphoma, severe acquired and congenital cytopenias, white and red blood cell abnormalities, and immunodeficiencies.
• Patients with acute lymphoblastic leukemia must be in morphological remission (< 5% blasts) at the time of transplant. Patients with acute non-lymphocytic leukemia will preferably be in morphologic remission but may be enrolled when aplastic after chemotherapy or with < 20% blasts. Patients with lymphoma must be in complete or close to complete remission (if residual adenopathy, PET scan must be negative or only have slight uptake, eg. SUV < 2).
• Patients must lack a healthy HLA-identical related donor of at least one year of age.
• Patient must have a mismatched related or an unrelated donor who is:

1. Able to receive G-CSF and undergo apheresis either through placement of catheters in antecubital veins or a temporary central venous catheter,

2. Healthy,

3. Willing,

4. For recipients of an unrelated donor transplant, recipient eligibility will be restricted as follows if in the judgment of the recipients' transplant physician, the recipient cannot receive a transplant with combined positive and negative fractions as described in Section 6.1.3.2 or an unmanipulated PBSC product.

5. Meets eligibility criteria for donors.

• If only one mismatched related relative is available, an acceptable unrelated donor must be identified as a backup.
• Patient or authorized guardian must sign informed consent for this study.

Exclusion Criteria:

• Patient with an anticipated life expectancy of < 1 month
• Active infectious hepatitis or CMV infection
• HIV or HTLV-I/II infection
• Serious infection (bacterial, fungal, viral) within the last 4 weeks
• Cardiac ejection fraction < 45%; can be lower if patient is not in clinical cardiac failure and a reduced intensity conditioning regimen is used.
• Creatinine clearance <60 ml/min/1.72 m2; can be lower if a reduced intensity conditioning regimen is used.
• Pulmonary diffusion capacity (adjusted for Hgb), FEV1, or FVC <60% of predicted or O2 sat < 94% if unable to perform PFTs; can be lower if a reduced intensity conditioning regimen is used.
• Serum ALT > 3 x upper limit of normal (can be up to 5 x upper limit of normal if a reduced intensity conditioning regimen is used) or bilirubin > 2. The bilirubin criteria for sickle cell disease patients is direct bilirubin >2x upper limit of normal.
• Performance score (Lansky/Karnofsky) < 50
• Any condition that compromises compliance with the procedures of this protocol, as judged by the principal investigator.

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Bone Marrow Failure
• Bone Marrow Failure Disorders
• Chronic Myeloid Leukemia
• Hemoglobinopathies
• Hemoglobinopathy
• Immune Deficiency
• Immunologic Deficiency Syndromes
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Lymphomas
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Osteopetrosis
• Pancytopenia
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Device:
• CliniMACS® (T cell depletion)
Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.

Locations

Country	Name	City	State
United States	Levine Children's Hospital, Carolinas Medical Center	Charlotte	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Severe Graft vs. Host Disease (GVHD).	Severe GVHD defined as grade III/IV GVHD.	Within 30 days after stem cell transplant
Secondary	Number of Participants With Engraftment and Time to Engraftment	Engraftment was measured as time to absolute neutrophil count >500	Within 28 days after stem cell transplant
Secondary	Number of Participants With Post-transplant Infections		1 year
Secondary	Number of Participants With EBV-related Post Transplant Lymphoproliferative Disorder (PTLD)		5 years
Secondary	Number of Participants With Post-transplant Leukemia Relapse		5 years
Secondary	Number of Participants With Transplant-related Mortality	Transplant-related mortality includes death due to regimen-related toxicity or GVHD (all causes other than disease relapse). Those who died due to disease relapse are not included in the analyzed population for that time point.	2 year
Secondary	Number of Participants With Transplant-related Toxicities		1 year
Secondary	Overall Survival		2 years
Secondary	Device Performance: Dose of CD34+ Cells and CD3+ Cells Given	For mismatched related donors, the target cell dose after processing is >/= 20 x 10^6 CD34+ cells/kg patient body weight, but >/= 8 x 10^6 is acceptable.; For unrelated donors the target cell dose after processing is >/= 10 x 10^6 CD34+ cells/kg patient body weight, but >/= 4 x 10^6 is acceptable.; The target T cell dose is	Length of the trial (5 years)